시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 속효성 인슐린 시장 보고서(2025년)
Short-Acting Insulin Global Market Report 2025
상품코드 : 1815895
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,348,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,176,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,004,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

속효성 인슐린 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.2%를 나타내 141억 4,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 정부에 의한 이니셔티브 증가, 정부 지원 증가, 생산에 있어서의 급속한 기술 혁신, 인슐린 요법의 채용 증가, 맞춤형 의료의 대두에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 인슐린 전달 장치와 기술의 진보, 혁신적인 속효성 인슐린 아날로그, 바이오시밀러의 개발, 환자 중심의 치료로의 이동, 제형의 진보 등이 있습니다.

향후 5년간의 성장률 5.2%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 0.3%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 덴마크와 푸에르토리코에서 공급되는 속효형 인슐린 아날로그의 가격을 상승시키고 포도당 통제를 손상시키고 내분비과의 치료비를 증가시킬 수 있으므로 당뇨병 치료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

1형 당뇨병의 유병률의 상승은 속효성 인슐린 시장 성장을 가속할 것으로 예측됩니다. 1형 당뇨병은 체내에서 인슐린 생산 세포가 파괴되는 자가면역 질환이며, 평생에 걸친 인슐린 요법이 필요합니다. 1형 당뇨병의 이환율 증가는 유전적 요인, 환경적 유인, 자가면역 질환 증가의 영향을 받고 있습니다. 단시간 작용 인슐린은 신속한 혈당 조절을 제공하고 신체의 자연적인 인슐린 반응을 모방하여이 상태를 관리하는 데 중요한 역할을 합니다. 예를 들어, 당뇨병에 대한 인식을 높이기 위한 단체인 Diabetes Australia는 2023년에 2022년에는 약 13만 4,000명의 호주인이 1형 당뇨병을 앓았으며, 그 수는 13만 5,423명으로 증가했다고 보고했습니다. 그 결과, 1형 당뇨병의 유병률 증가가 속효성 인슐린 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Short-acting insulin is a type of insulin used to manage blood sugar levels during or after meals. It begins acting within 30 minutes to 1 hour, peaks around 2-3 hours, and lasts for approximately 4-6 hours. This insulin type plays a crucial role in glucose regulation by promoting glucose uptake into cells for energy, particularly after food consumption.

The main formulations of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin variant used to control blood sugar levels, typically administered before meals. These formulations are available in various dosage forms, including vials, pre-filled pens, and cartridges, and can be administered via subcutaneous or intravenous routes. Short-acting insulin is prescribed for both type 1 and type 2 diabetes patients and is distributed through retail pharmacies, hospital pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides short-acting insulin market statistics, including the short-acting insulin industry global market size, regional shares, competitors with the short-acting insulin market share, detailed short-acting insulin market segments, market trends, and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The short-acting insulin market size has grown steadily in recent years. It will grow from $11 billion in 2024 to $11.54 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to an increase in the type 1 diabetes population, a rising geriatric population, a surge in research and development funding, the prevalence of diagnosed instances, and increasing urbanization.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to an increase in initiatives taken by the government, an increase in government support, rapid innovations in production, increasing adoption of insulin therapy, and the rise of personalized medicine. Major trends in the forecast period include advancements in insulin delivery devices and technologies, innovative fast-acting insulin analogs, the development of biosimilars, a shift towards patient-centric care, and advancements in formulation.

The forecast of 5.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder diabetic care by inflating prices of rapid-acting insulin analogs sourced from Denmark and Puerto Rico, potentially compromising glucose control and increasing endocrinology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of type 1 diabetes is expected to drive the growth of the short-acting insulin market. Type 1 diabetes is an autoimmune condition in which the body destroys insulin-producing cells, necessitating lifelong insulin therapy. The increasing incidence of type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin plays a crucial role in managing the condition by providing rapid blood sugar control and mimicking the body's natural insulin response. For example, in 2023, Diabetes Australia, an organization dedicated to raising awareness about diabetes, reported that approximately 134,000 Australians were living with type 1 diabetes in 2022, a number that increased to 135,423 in 2023. As a result, the growing prevalence of type 1 diabetes is fueling the expansion of the short-acting insulin market.

Leading companies in the short-acting insulin market are developing innovative products such as insulin pods to enhance insulin delivery and improve adherence for diabetes patients. An insulin pod is a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. In April 2023, Insulet Corporation, a US-based medical device company, received FDA clearance for Omnipod GO, a pioneering basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device delivers continuous insulin without requiring a separate controller. By eliminating the need for daily injections and offering pre-programmed insulin rates, Omnipod GO simplifies diabetes management. Its user-friendly design and pharmacy accessibility enhance convenience for both patients and healthcare providers, reinforcing Insulet's commitment to advancing diabetes care through innovative technology.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired the Humulin range in India from Eli Lilly & Company for an undisclosed amount. This acquisition strengthens Lupin's position in the Indian insulin market by expanding its product portfolio with the addition of Huminsulin from Eli Lilly & Company. Eli Lilly & Company, a US-based pharmaceutical firm, specializes in insulin products, including short-acting insulin, further reinforcing Lupin's commitment to providing comprehensive diabetes care solutions.

Major players in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., and Adocia S.A.S.

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short-acting insulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short-Acting Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short-acting insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for short-acting insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The short-acting insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Short-Acting Insulin Market Characteristics

3. Short-Acting Insulin Market Trends And Strategies

4. Short-Acting Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Short-Acting Insulin Growth Analysis And Strategic Analysis Framework

6. Short-Acting Insulin Market Segmentation

7. Short-Acting Insulin Market Regional And Country Analysis

8. Asia-Pacific Short-Acting Insulin Market

9. China Short-Acting Insulin Market

10. India Short-Acting Insulin Market

11. Japan Short-Acting Insulin Market

12. Australia Short-Acting Insulin Market

13. Indonesia Short-Acting Insulin Market

14. South Korea Short-Acting Insulin Market

15. Western Europe Short-Acting Insulin Market

16. UK Short-Acting Insulin Market

17. Germany Short-Acting Insulin Market

18. France Short-Acting Insulin Market

19. Italy Short-Acting Insulin Market

20. Spain Short-Acting Insulin Market

21. Eastern Europe Short-Acting Insulin Market

22. Russia Short-Acting Insulin Market

23. North America Short-Acting Insulin Market

24. USA Short-Acting Insulin Market

25. Canada Short-Acting Insulin Market

26. South America Short-Acting Insulin Market

27. Brazil Short-Acting Insulin Market

28. Middle East Short-Acting Insulin Market

29. Africa Short-Acting Insulin Market

30. Short-Acting Insulin Market Competitive Landscape And Company Profiles

31. Short-Acting Insulin Market Other Major And Innovative Companies

32. Global Short-Acting Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short-Acting Insulin Market

34. Recent Developments In The Short-Acting Insulin Market

35. Short-Acting Insulin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기